LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital

Similar documents
The Lymphomas. An overview..

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Lymphoma and Myeloma Kris3ne Kra4s, M.D.

Lymphoma: The Basics. Dr. Douglas Stewart

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Indolent Lymphomas: Current. Dr. Laurie Sehn

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe

Lymphatic system component

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008

Monsanto s Spin on its Roundup herbicide is Unwinding

Corporate Medical Policy

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

Non-Hodgkin Lymphoma in Clinically Difficult Situations

2012 by American Society of Hematology

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

Evaluation of Neck Mass. Disclosure. Learning Objectives 3/24/2014. Karen T. Pitman MD, FACS Banner MDACC, Gilbert AZ. Nothing to disclose

Lymphoma John P. Leonard, M.D.

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

SEQUENCING FOLLICULAR LYMPHOMA

Bosch et al. BMC Cancer (2018) 18:276 /s y

Bendamustine for relapsed follicular lymphoma refractory to rituximab

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Stage 4 bone cancer life expectancy

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Leukemia And Lymphoma In The Nervous System

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

Cancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma

Head and Neck: DLBCL

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India

Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013.

HIV ASSOCIATED LYMPHOMA. Dr N Rapiti

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Non-Hodgkin lymphoma

Blood Cancers in the Community

Approach to Thyroid Nodules

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology

Lymphatic System Disorders

The spectrum of flow cytometry of the bone marrow

MANAGEMENT OF LYMPHOMAS

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

C r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S

Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology

Approach to Core Biopsy Specimens

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

Frequency and Pattern of Bone Marrow Infiltration in Non- Hodgkin s Lymphoma

Lymphoma Read with the experts

Lugano classification: Role of PET-CT in lymphoma follow-up

Imbruvica. Imbruvica (ibrutinib) Description


During past decades, because of the lack of knowledge

Follicular Lymphoma 2016:

Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?

Mathias J Rummel, MD, PhD

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date

Non-Hodgkin Lymphoma Early Detection, Diagnosis, and Staging

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

Medcenter One Cancer Committee 2011 Annual Report

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Notification to Implement Issued by pcodr: December 14, 2012

Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich

B. Misunderstanding about clinical trials as an effective option to treatment; and

Abstracting Hematopoietic Neoplasms

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Case 4 Diagnosis 2/21/2011 TGB

CLINICAL MEDICAL POLICY

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

TREATMENT CONSIDERATIONS IN CLL/SLL AND FL. June 6, 2018

Update: Non-Hodgkin s Lymphoma

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

Pathology of Hematopoietic and Lymphoid tissue

Immunopathology of Lymphoma

Pathology of Hematopoietic and Lymphoid tissue

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Splenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc.

S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009

An Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review

Non-Hodgkin s Lymphomas Version

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

Transcription:

LYMPHOMA DIAGNOSIS and PROGNOSIS LC Lim Dept of Hematology Singapore General Hospital

OUTLINE Accurate diagnosis Define subtype : WHO classification Staging : Defines extent of involvement Prognosis Determining Prognosis Prognostic scores Communication of Diagnosis & Prognosis Six Steps

LYMPHOMA DIAGNOSIS

DIAGNOSIS OF LYMPHOMA Tissue diagnosis is essential excisional lymph node biopsy is definitive procedure Attempt to remove intact lymph node to avoid trauma to nodal architecture Fine needle aspiration (FNA) should not be used for definitive diagnosis and subtyping Lymph node Well, prepared, formalin-fixed, paraffinembedded sections required

Tissue Diagnosis (Lymph Node Biopsy) Consider performing lymph node biopsy if >40yrs Supraclavicular location Node diameter >2cm Firm to hard texture Lack of tenderness Do Full blood count and CXR before biopsy

WHO Classification of Lymphoma (2008) Internationally accepted taxonomy for lymphoma Fundamental to the classification, diagnosis and management of lymphoma 1. B-cell 2. T-cell and NK-cell 3. Hodgkin s 4. B-cell proliferations of uncertain malignant potential

Staging of Disease Stages - I, II, III, IV A or B - Based on presence/not of B symptoms fever night sweats weight loss

LYMPHOMA PROGNOSIS

Determining Prognosis Forecast of probable course and outcome of a disorder or disease Life expectancy Prognostication is both art and science, and is imperfect at best

How to Determine Prognosis? Sources physician predictions stage-specific survival data tumor-specific prognostic factors (eg, molecular markers, stage, grade, etc) integrated models of prognosis IPI, FLIPI, Hasenclever index for Hodgkin s lymphoma treatment- and patient-specific factors (eg, comorbid illness, performance status, and disease signs and symptoms)

LOW GRADE LYMPHOMA Indolent survival of untreated disease measured in years usually not curable by conventional therapy may have prolonged survival even if treatment results in only partial response EG Follicular lymphoma, CLL, Marginal zone lymphoma (eg SLVL), Hairy cell leukemia

AGGRESSIVE LYMPHOMA Comprises at least 10 distinct WHO categories About 50% of NHL Eg Diffuse large cell peripheral T cell anaplastic large cell lymphoma

AGGRESSIVE LYMPHOMA survival of untreated disease measured in months possibility of cure with conventional therapy only patients attaining complete response to therapy can expect reasonable survival or cure rapidly fatal within weeks to months if untreated or unresponsive to therapy

INTERNATIONAL PROGNOSTIC INDEX AGGRESSIVE NHL

FOLLICULAR LYMPHOMA IPI

Assessing Performance Status Performance status quantifies the functional status of cancer patients Tools such as the Karnofsky Scale, ECOG also captures medical care requirements Since the beginning of modern oncology in the 1940s, the ability of a patient to perform routine activities of daily living has shown the best correlation with prognosis.

ECOG Performance Scale 0 = fully active, able to carry out all normal activities 1 = symptoms present but able to carry out normal activities, some difficulty with more strenuous activities 2 = able to carry out normal self-care activities but limited in ability to work. Up and about more than 50% of time 3 = capable of only limited self-care. Confined to bed or chair more than 50% of waking hours 4 = completely disabled. Needs full time assistance with normal self-care activities

LYMPHOMA COMMUNICATING DIAGNOSIS & PROGNOSIS

Disclosing Diagnosis and Prognosis Research has shown that physicians are systematically overly optimistic in formulating survival estimates and even more optimistic when they disclose prognostic information to patients and/or their families Physicians' estimates of prognosis for patients in palliative care programs are overly optimistic by a factor of 3- to 5-fold -- that is 300% to 500% more optimistic than observed

6-Step Protocol: SPIKES SPIKES Setting 6-Step Protocol to Clarify Diagnosis and Prognosis 1. Getting started Perception Invitation Knowledge Emotion 2. What does the patient know? 3. How much does the patient want to know? 4. Share the information 5. Respond to feelings Subsequent 6. Plan next steps and follow up

Key Take Home Points Accurate assessment and disclosure of diagnosis and prognosis are essential for both treatment and personal decision-making for patients with cancer Consider 6-step SPIKES protocol for effective communication

Thank You Medicine Review Course 2011 Haematology Lymphoma Diagnosis & Prognosis